News
2d
Clinical Trials Arena on MSNVir’s hepatitis B combo falls short in Phase II trialVir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.
Hosted on MSN4d
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025The findings, highlighted across five posters, underscored significant advancements in achieving functional cures for chronic ...
Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...
Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...
The Knox County Health Department shared in a press release that each May, the United States observes Hepatitis Awareness Month to bring attention to viral hepatitis and ...
Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...
A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.
A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...
Hepatitis B. It’s primarily spread through bodily ... Your doctor will find the source of the problem and work with you on the right treatment.
The focus of treatment is instead placed on easing symptoms ... A vaccines known as Havrix and Vaqta or the Twinrix vaccine which combine both the hepatitis A and B vaccines. The CDC recommends ...
Monoclonal B-cell lymphocytosis (MBL) is estimated to affect about 5–12% of people. It doesn’t cause symptoms and doesn’t require active treatment. However, a subtype called high-count MBL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results